title: [Role of adjuvant chemoradiotherapy in the treatment of gastric carcinoma].
abstract: Gastric carcinoma is often diagnosed at the advanced stage. Approximately 50% of patients with locoregional disease cannot undergo any curative resection. 5-year survival rate in patients who undergo a curative resection (R0) ranges from 30-40%. In patients with curatively resected gastric carcinoma who are at high risk of relapse the adjuvant postoperative chemotherapy with 5-FU/leucovorin is recommended. It should be followed by radiotherapy with concomitant 5-FU/leucovorin, and then two more courses of 5-FU/leukovorin (INT-0116 trial) should be added. For the surgery alone group, the overall survival was 27 months; in the chemoradiotherapy group it was 36 months. The recommended therapy for inoperable or medically unsuitable patients with locoregional carcinoma is the combined radiation therapy (45 to 50.4 Gy) with concurrent 5-fluorouracil or cisplatin based chemotherapy.
authors.affiliation: Klinika komplexní onkologické péce-oddĕlení radiacní onkologie, Masarykův onkologický ústav, Brno. kocakova@mou.cz
authors.forename: I
authors.initials: I
authors.lastname: Kocáková
authors.forename: H
authors.initials: H
authors.lastname: Vetchá
authors.forename: R
authors.initials: R
authors.lastname: Soumarová
authors.forename: R
authors.initials: R
authors.lastname: Vyzula
mesh_terms: D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D018714:Radiotherapy, Adjuvant; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery